definiens: ), as amended by Amendment No . 1 ( ( defined below ), Amendment No . 2 ( definedbelow ) and Amendment No . 3 ( defined below ) ( as so amended, the ), pursuant to which Buyer acquiredthe Purchased Assets from [COMPANY] ; WHEREAS, Buyer and [COMPANY] entered into Amendment No . 1 to Asset Purchase Agreement as of March 4,2015 ( ), pursuant to which Buyer acquired the New ANDAs from [COMPANY] on the same terms andconditions as the Original Agreement, except for changes required to reflect ( i ) the date of the purchase of the NewPurchased Assets thereunder, ( ii ) the payment of the Third Payment upon execution of the New Bill of Sale and ( iii ) adifferent Royalty percentage to be paid with respect to the New Products under the New ANDAs, in each case asreflected in Amendment No . 1 ( with all such capitalized terms having the same meaning as defined in AmendmentNo . 1 ) ; WHEREAS, Buyer and [COMPANY] entered into Amendment No . 2 to Asset Purchase Agreement as of July 10,2015 with respect to the generic pharmaceutical products set forth therein ( ) that Buyer alsowished to acquire on and pursuant to the terms of the Original Agreement ( as amended by Amendment No . 1 ) ; WHEREAS, Buyer and [COMPANY] entered into Amendment No . 3 to Asset Purchase Agreement as of December11, 2015 with respect to the generic pharmaceutical products set forth therein ( ) which wereinadvertently excluded from Amendment No . 2 and which Buyer also wished to acquire on and pursuant to the termsof the Original Agreement ( as amended by Amendment No . 1 and Amendment No . 2 ) ; WHEREAS, pursuant to the Agreement and in consideration of the Purchased Assets, Buyer agreed to payTeva a Royalty on a Product by Product basis ; and WHEREAS, Buyer and [COMPANY] have agreed to amend the terms of the Agreement to provide for the terminationof the Royalty with respect to each of the ANDAs and Products set forth on Exhibit A hereto ( together, the ) and the payment of the Amendment No . 4 Payment